ArticleeLife2020
Evolved bacterial resistance against fluoropyrimidines can lower chemotherapy impact in the
Article in eLife, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 35 citations in OpenAlex.
- Nonantibiotic-driven evolution reveals rare but predictable routes to broad antibiotic resistance.mBio · 2026Article
- Probiotics mitigate non-antibiotic drug-induced dysbiosis via protein homology-driven competitive binding.Nature communications · 2026Article
- Human colitis-associated colorectal carcinoma progression is accompanied by dysbiosis with enriched pathobionts.Gut microbes · 2025Article
- Predicting drug inactivation by changes in bacterial growth dynamics.npj antimicrobials and resistance · 2025Article
- Article
- Expansion of a bacterial operon during cancer treatment ameliorates fluoropyrimidine toxicity.Science translational medicine · 2025Observational
- A thiouracil desulfurase protects Clostridioides difficile RNA from 4-thiouracil incorporation, providing a competitive advantage in the gut.Cell host & microbe · 2025Article
- Pharma[e]cology: How the Gut Microbiome Contributes to Variations in Drug Response.Annual review of pharmacology and toxicology · 2025Review
- Expansion of a bacterial operon during cancer treatment ameliorates drug toxicity.bioRxiv : the preprint server for biology · 2024Article
- Metagenomic analysis during capecitabine therapy reveals microbial chemoprotective mechanisms and predicts drug toxicity in colorectal cancer patients.medRxiv : the preprint server for health sciences · 2024Article
- Natural Compounds for Bone Remodeling: A Computational and Experimental Approach Targeting Bone Metabolism-Related Proteins.International journal of molecular sciences · 2024Article
- Antibacterial activity of nonantibiotics is orthogonal to standard antibiotics.Science (New York, N.Y.) · 2024Article
- Improvement of the Genome Editing Tools Based on 5FC/5FU Counter Selection inMicroorganisms · 2023Article
- Functional Assay for Measuring Bacterial Degradation of Gemcitabine Chemotherapy.Bio-protocol · 2023Article
- Article
- The cancer chemotherapeutic 5-fluorouracil is a potent Fusobacterium nucleatum inhibitor and its activity is modified by intratumoral microbiota.Cell reports · 2022Article
- Host and gut bacteria share metabolic pathways for anti-cancer drug metabolism.Nature microbiology · 2022Article
- Bacterial diet modulates tamoxifen-induced death via host fatty acid metabolism.Nature communications · 2022Article
- Tunable transcription factor library for robust quantification of regulatory properties in Escherichia coli.Molecular systems biology · 2022Article
- Assembling stable syntrophic Escherichia coli communities by comprehensively identifying beneficiaries of secreted goods.Cell systems · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
Abstract
Metabolism of host-targeted drugs by the microbiome can substantially impact host treatment success. However, since many host-targeted drugs inadvertently hamper microbiome growth, repeated drug administration can lead to microbiome evolutionary adaptation. We tested if evolved bacterial resistance against host-targeted drugs alters their drug metabolism and impacts host treatment success. We used a model system of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.